Blueprint Medicines Corp (BPMC)
107.19
+0.19
(+0.18%)
USD |
NASDAQ |
May 03, 16:00
107.20
+0.01
(+0.01%)
After-Hours: 20:00
Blueprint Medicines Revenue (TTM): 249.38M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 249.38M |
September 30, 2023 | 216.20M |
June 30, 2023 | 225.62M |
March 31, 2023 | 204.59M |
December 31, 2022 | 204.04M |
September 30, 2022 | 272.28M |
June 30, 2022 | 230.49M |
March 31, 2022 | 221.24M |
December 31, 2021 | 180.08M |
September 30, 2021 | 107.16M |
June 30, 2021 | 828.10M |
March 31, 2021 | 809.14M |
December 31, 2020 | 793.73M |
September 30, 2020 | 811.16M |
June 30, 2020 | 75.18M |
March 31, 2020 | 71.95M |
December 31, 2019 | 66.51M |
Date | Value |
---|---|
September 30, 2019 | 16.01M |
June 30, 2019 | 7.968M |
March 31, 2019 | 44.30M |
December 31, 2018 | 44.52M |
September 30, 2018 | 45.12M |
June 30, 2018 | 52.09M |
March 31, 2018 | 16.54M |
December 31, 2017 | 21.43M |
September 30, 2017 | 27.49M |
June 30, 2017 | 25.58M |
March 31, 2017 | 26.76M |
December 31, 2016 | 27.77M |
September 30, 2016 | 24.72M |
June 30, 2016 | 21.98M |
March 31, 2016 | 17.60M |
December 31, 2015 | 11.40M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
7.968M
Minimum
Jun 2019
828.10M
Maximum
Jun 2021
294.25M
Average
216.20M
Median
Sep 2023
Revenue (TTM) Benchmarks
Apellis Pharmaceuticals Inc | 396.59M |
Alnylam Pharmaceuticals Inc | 2.003B |
Ionis Pharmaceuticals Inc | 787.65M |
Madrigal Pharmaceuticals Inc | -- |
Sarepta Therapeutics Inc | 1.403B |